| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2010: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2009: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2008: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Research Abstract |
EGFR tyrosine kinase inhibitor confers often dramatic response in lung cancer harboring EGFR mutation. However, virtually all the tumors acquire resistance. For large fraction of lung cancer, a efficacious therapeutic target is not known. In this study, we confirmed the HER2 mutation or MET amplification could be the therapeutic target although their incidences were low. Furthermore, we found a reciprocal relationship between T790M secondary mutation of the EGFR gene and MET amplification in acquire resistance.
|
